drugset / Trial / NCT01305655
Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL
Phase 3
Completed
47 enrolled
Nordic Society for Pediatric Hematology and Oncology
Lund University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Early intervention in children and adolescents who experience delayed MTX-clearance and renal dysfunction in ALL treatments with the enzyme Glucarpidase which rapidly hydrolyses MTX to non-toxic metabolites to avoid life threatening complications.
Timeline
- Start
- 2008-07
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glucarpidase | Protein / enzyme biologic | 50 iu/kg | — |